The humanized mouse model market is expected to reach USD 113.6 Million by 2025 and is expected to steadily grow at a CAGR of 5.8% to reach USD 199.7 Million by 2035. In 2024, humanized mouse model market have generated roughly USD 107.4 Million in revenues.
The humanized mouse model is a transgenically modified mouse that carries viable human genes, cells, or tissues useful in biomedical research. Advances in genetic engineering, especially CRISPR, have manipulated humanized models so that they may become more precise, thereby increasing the reliability in drug testing. Besides those, there is an increasing demand for personalized medicines, which have also added to the rising number of whole-model usages because they could predict individual drug responses.
The most steadily increasing application of research on humanized models is that of cancer and autoimmune diseases, with special focus on the (mounting) immuno-oncology research using checkpoint inhibitors and CAR-T cell therapies. With this, demand has also grown in terms of infection research, particularly in the area of HIV, COVID-19, and hepatitis, and has indeed led to an acceleration in the demand for humanized mouse models in characterizing human immune responses and identifying targeted therapies.
Key Market Metrics
| Metric | Value |
|---|---|
| Industry Size (2025E) | USD 113.6 Million |
| Industry Value (2035F) | USD 199.7 Million |
| CAGR (2025 to 2035) | 5.8% |
There were significant historical reasons for the wide acceptance of the humanized mouse models in biomedical sciences during the years 2020 to 2024. The COVID-19 pandemic fast-tracked their application, allowing scientists to work on advanced models to study viral infection, immune responses, and vaccine development.
During the same growth period of CRISPR/gene-editing tool development and enhancement, humanized models were increasingly rendered efficient and precise for easy availability through what became very mild regulations, whereas, in recent years, regulatory changes have focused on giving priority to alternative methods over conventional animal testing, further enhancing their uptake, especially for drug safety and toxicology.
In this context, the growing interest in personalized medicine and preclinical assays for orphan diseases now forms yet another growing area for the applications of humanized mouse models, thus anchoring it as a major name in translational research
Higher expenditures on biopharmaceutical R&D in cancer, immunology, and infectious diseases are driving the more extensive usage of humanized mouse models in North America. Furthermore, FDA regulatory support for non-traditional testing models has resulted in their much wider application for safety and efficacy trials.
The availability of academic research centers and leading contract research organizations (CROs) further supports demand. The growing trend of personalized medicine along with technological advancements in CRISPR and gene editing have also increased the use of these models in precision research and firmly established them in drug discovery and translational medicine.
Innovative preclinical drug development models are some of the focus areas of the EMA, thereby prompting pharma and biotech companies to give preference for humanized models in increasing the translational relevance of their studies.
This will be complemented by regulations and further ethical regulations existing in the region to reduce animal testing. More humanized models, which could represent more human immune response data, have become in demand in the wake of these developments.
Increasing investments in precision medicine and stem-cell research, and the location of the best-tiered academic and research organizations are further drivers of demand. Advances in CRISPR and gene-editing technologies also make these models more efficient and relevant to preclinical research.
The sales of humanized mice models have increasing sales throughout Asia Pacific region and that includes growth driven mainly on the increase in biomedical research spending by countries like China, Japan and South Korea. Governments have poured money into drug-discovery, oncology research and immunotherapy which has led to the greater uptake of such models for preclinical research.
Greater availability of CRISPR and gene-editing technologies improves capability of local scientists to develop sophisticated models. Challenges posed by global collaboration and coordinating laws with Western countries enable wider applications making Asia Pacific one of the burgeoning markets for humanized mouse models.
High Cost and Technical Complexity Hinders the Adoption of Humanized Mouse Model
The primary disadvantage in terms of adoption of humanized mouse models remains their extremely costly and technically demanding status. Their generation-and maintenance-require specialized knowledge, state-of-the-art genetic engineering techniques, and immunological alterations to an extent that they are far more expensive than their classical counterparts.
Moreover, extended gestation periods coupled with poor breeding efficiencies only make matters worse in terms of cost and render such models low on scalability.Furthermore, variability with engraftment success and variation in immune response will add to the experimental unpredictability of these models, therefore demanding an extra level of procedure validation.
Rising Demand for Infectious Disease Researchposes significant opportunity for humanized mouse model
Humanized mice are critical for modeling human-specific pathogens such as HIV, SARS-CoV-2, Zika, and the hepatitis viruses that otherwise do not infect conventional mouse models. Following continuous advances in antiviral drug discovery and vaccine development, humanized mice are presently employed by the pharmaceutical and biotechnology industry for testing novel therapies in settings of human immune systems helmeting physiologically relevant counterparts.
Furthermore, global pandemics preparedness programs and an increase in concerns regarding antimicrobial resistance (AMR) are creating a necessity for advanced preclinical models that may closely mimic human responses. Increased government and research institutional investment in infectious disease modeling is accelerating humanized mouse market development.
Expanding Role in Immuno-Oncology Research Surges the Growth of the Market
Humanized mouse models occupy center stage in immuno-oncology drug discovery, where human immune cells can be studied for interaction with cancer. The pharmaceutical industry, in turn, is finding increasing applicability of these models in the screening of immune checkpoint inhibitors, CAR-T therapies, and monoclonal antibodies. Compared with more isolated conventional models, humanized mice are highlighting safety and efficacy methods for rapid clinical translation in immunotherapy.
Towards developing cancer immunotherapies, leading biotech and pharmaceutical companies have invested substantially in improving engraftment methodologies and in the development of customized humanized models to specifically interrogate certain cancers, thus driving demand on the part of such preclinical reagents.
Rising Adoption in Infectious Disease Research Anticipates the Growth of the Market
The need for more efficacious models in infectious diseases prompted the increasing usage of humanized mouse models, especially in research relating to viral infections such as HIV, hepatitis, and tuberculosis.Research organizations and pharmaceutical companies utilize these models extensively to design new therapeutic avenues against novel and re-emerging infectious diseases.
Further, public health agencies and regulatory bodies would also support funding programs for the application of humanized mice to dissecting the pathogenesis of the disease and drug responses, thus paving the way for industry development.
Expansion of Hematopoietic Stem Cell (HSC)-Humanized Models
Amongst the emerging trends in humanized mouse research is the generation of advanced HSC-humanized models that support long-term engraftments for functional human immune cells. These models offer a more relevant platform for studying autoimmune diseases, chronic inflammation, and hematological tumors.
The HSC-humanized mouse model is now gaining increasing acceptance by pharmaceutical companies to assess next-generation immunotherapies targeted at bispecific antibodies and cytokine-based therapies. In the same vein, there is increased emphasis on streamlining engraftment and immune cell differentiation for a more reproducible and consistent model of drug development and disease modelling.
Increasing Use in Transplantation and Graft-Versus-Host Disease (GVHD) Research
With rising cases of organ transplantation worldwide, organ transplant scientists are working on these models to study compatibility of immune responses and tolerance-creating approaches to organ transplant patients. The pharmaceutical industry is using humanized models for the screening of new immuno-suppressants toward decreasing rejection rates in transplants.
The increasing rates of bone marrow and stem cell transplantation, together with the rising technology in human immune system reconstruction are creating further demand for these models in transplantation studies.
Between 2020 and 2024, market growth was stimulated by rising demand for preclinical drug testing; increased funding for infectious diseases and oncology research; and improvements to the methodology for the reconstruction of immune systems. The COVID-19 pandemic also sped up the use of the model in the development of antivirals, drugs, and vaccines.
For the period 2025 to 2035, growth would be further stimulated by advances in stem cell engraftment, research on transplantation, and hematopoietic models. The demand further fueled by increasing applications in autoimmune disease, regenerative medicine, and transplantation studies. Increased funding and regulatory support in conjunction with pharma collaborations will drive continuous innovations and wider acceptance across various research domains.
| Category | 2020 to 2024 Trends |
|---|---|
| Regulatory Landscape | Enhanced ethical oversight, rigorous compliance for animal testing, and increased acceptability of humanized models in preclinical research. |
| Technological Advancements | Progress in immune system reconstitution, better engraftment methods, and increased model consistency for oncology and infectious disease research. |
| Consumer Demand | Increased demand by pharmaceutical and biotech companies for cancer, immunotherapy, and virology research. |
| Market Growth Drivers | Expansion in personalized drug development, expanded research funding, and increasing incidence of infectious diseases. |
| Sustainability | Emphasis on ethical animal testing, animal testing redundancy reduction, and enhanced welfare standards. |
| Category | 2025 to 2035 Projections |
|---|---|
| Regulatory Landscape | Harmonization of international regulations, increased focus on ethical options, and wider approval routes for humanized models in drug development. |
| Technological Advancements | Improved immune system function, increased use in autoimmune diseases, and more sophisticated transplantation models for research precision. |
| Consumer Demand | Wider application in regenerative medicine, organ transplant studies, and wider uptake in rare disease modeling. |
| Market Growth Drivers | Wider clinical uses, increased partnership between academia and industry, and increasing uptake in next-generation therapeutics. |
| Sustainability | Integration of other models, progress in minimizing the use of live animals, and ethical improvements in genetic modification procedures. |
Market Outlook
The greatest market of humanized mouse models is by far the USA because much spending on research and development is directed to cancer immunotherapy, infectious disease, and autoimmune disease. There are other reasons why the market has high growth, such as the presence of leading pharma companies and strong academic research supported by NIH funding. Adoption is further driven due to increasing FDA approvals of humanized models for preclinical drug testing.
Market Growth Factors
Market Outlook
| Country | CAGR (2025 to 2035) |
|---|---|
| United States | 3.2% |
Market Outlook
This country is very strong on biomedical research and has a very stringent regulatory environment which really advances the use of humanized mouse models. Further spurred on by the nation's advances in oncology and immunotherapy research and the increasing number of pharmaceutical partnerships within Germany, the market grows. Increasing amounts of government funding made available for translational medicine and studies on drug effectiveness accelerates demand further into the nation.
Market Growth Factors
Market Forecast
| Country | CAGR (2025 to 2035) |
|---|---|
| Germany | 3.8% |
Market Outlook
Emergence of biotechnology industries and increasing number of contract research organizations (CROs), in addition to focus on vaccine and drug development, thus many factors propelling growth. Through funding programs and the relaxation of clinical trial regulations, there are also incentives from the government that enhance adoption.
People are becoming increasingly aware of the requirement for research on humanized mouse models, and so in above factors, there are increasing global partnerships that further strengthen demand.
Market Growth Factors
Market Forecast
| Country | CAGR (2025 to 2035) |
|---|---|
| India | 5.6% |
Market Outlook
The market for humanized mouse models in China is growing at an extremely rapid pace due to the investment in translational research and precision medicine in China. Activities funded by the government for the improvement of drug discovery, expanding biotech firms, and enhanced requirement for immuno-oncology research boost the market growth. Another area of growth for local CROs that further endorses adoption in pharma R&D.
Market Growth Drivers
Market Forecast
| Country | CAGR (2025 to 2035) |
|---|---|
| China | 6.2% |
Market Outlook
Japan has advanced research capabilities and puts much weight on regenerative medicine and stem cell research. All these act towards propelling the market for humanized mouse models. The aging of the population in Japan thus adds to a higher demand for preclinical research towards age-related disorders. Infrastructures and government policies further improve the academia-pharma collaboration towards the increased use of these models.
Market Growth Drivers
Market Forecast
| Country | CAGR (2025 to 2035) |
|---|---|
| Japan | 4.8% |
The genetic segment dominates the humanized mouse model market due to its high precision
Genetic segment carrying maximum share of its own in humanized mouse model market with an ultimate virtue of precision in replicating human-like genetic and immune system. Modification or replacement of mouse genes by human genes in such models thus produces reproducible modeling of human diseases in the field of oncology, immunology, and in metabolic diseases.
Genetic humanized mice are important for long-term drug development studies and toxicology tests giving stable reproducible results. Furthermore, their market position is supported because of their increased preclinical use by pharmaceutical and biotech companies, which need rigorous regulatory standards for improved translatability of animal models.
The cell-based segment holds a significant share due to its essential role in cancer immunotherapy,
Cell-based segment holds substantial share, its applications include cancer immunotherapy, studies in infectious disease, and regenerative medicine. These models are created by implantation of human cells, usually HSC or PBMC, to immunosuppressed mouse hosts to enable investigation of human immune function in vivo.
Such models are finding greater attention in testing for cell-based modalities involving CAR-T cells and stem cell therapeutics. Further, the models are receiving increased importance in understanding human diseases in an in vivo biological context with ever-increasing interest in personalized medicine and advancements in the technology of cell engraftment.
The pharmaceutical & biotechnology companies segment dominates the market due to its extensive use in preclinical drug development
Pharmaceutical and biotechnology companies create humanized mouse models to assist in studying in terms of drug efficacy, toxicity, and pharmacokinetics, before embarking on clinical trials. This allows them to reduce the chances of late-stage failures. Increasing interest in biologics, immunotherapies, and gene therapies also demands more such models.
In particular, stringent regulatory demands necessitate such models relevant to humans, further incentivizing pharma companies to utilize humanized mice in cancer, infectious diseases, and autoimmune diseases. With more expenditures directed to R&D and strategic collaborations, have segment to hold dominant position in the market.
The contract research organizations (CROs) segment holds a substantial share as pharmaceutical and biotech firms increasingly outsource preclinical studie
High-cost revenues come from the specialized expertise, sophisticated humanized models, and cost-saving high-throughput screening facilities that CROs provide. The rising sophistication related to biologic drugs as well as personalized medicine continuously leads to increased demands for niche solutions from contract research organizations in the area of developing humanized mouse models to study particular diseases.
It also contains long-term financing of contracted research, which further underpins the rise in internationalization of clinical trials since these CROs enable passing through regulatory approval and further accelerating the drug discovery pipeline in terms of costs.
Intense competition is present in the humanized mouse model market due to the emergence of technical advancement in genetic engineering people on the side of the regulatory authorities and huge demand for preclinical models that will map onto clinical outcome accurately. Authorities such as the FDA and EMA focusing on ethical issues and replicability during drug testing will further determine market trends.
Market leaders secure their share through alliances with pharma companies, biotech industries, and academia to develop disease-specific humanized models. On these premises, regional players throw challenges to global leaders with inexpensive alternatives, specialized localized settings, and scalable research services. On the balance of the emerging market for lucrative opportunities, competition is thrown by innovative pricing mechanisms, enhanced CRO collaborations, and making of tailored models.
Market Share Analysis by Company
| Company Name | Estimated Market Share (%) |
|---|---|
| Ingenious Targeting Laboratory | 33.6% - 38.5% |
| Axenis S.A.S | 20.4% - 22.6% |
| Trans Genic Inc. | 15.1% - 17.2% |
| Horizon Discovery Group PLC | 4.6% - 6.8% |
| Other Companies (combined) | 12.1% - 15.4% |
| Company Name | Key Offerings/Activities |
|---|---|
| Ingenious Targeting Laboratory | Ingenious Targeting Laboratory houses the market-leading customizable genetically engineered mice models in humanized mice-for all applications in immuno-oncology, neurodegenerative diseases, and metabolic diseases-. |
| Axenis S.A.S | Axenis S.A.S is leading in the provision of immunocompromised and humanized mouse models for use within the scope of preclinical research, especially on infectious disease and oncology research |
| Trans Genic Inc. | Trans Genic Inc. provides genetically engineered mouse models containing humanized immune systems for drug development and biomedicine applications. The company generates accurate models through patented gene modification technology, which qualitatively improves preclinical immunotherapy studies and those of regenerative medicine |
| Horizon Discovery Group PLC | Horizon Discovery Group PLC is an advanced company in the humanized mouse model arena, providing advanced gene editing murine models to underpin research in oncology and genetic diseases. The CRISPR-based genome engineering by Horizon combines the two activities to get customized preclinical models to the streamline pipelines of drug development for biotech and pharma industries. |
Key Company Insights
Genetic, and Cell-based (CD34, PBMC and BLT)
Oncology, Immunology and Infectious Diseases, Neuroscience, Toxicology, Hematopoiesis and Other Applications
Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Academic & Research Institutions
The overall market size for humanized mouse model market was USD 113.6 Million in 2025.
The humanized mouse model market is expected to reach USD 199.7 Million in 2035.
Expanding Cancer Research and Immunotherapy Development anticipates the growth of the humanized mouse model market.
The top key players that drives the development of humanized mouse model market are Ingenious Targeting Laboratory, Axenis S.A.S, Trans Genic Inc., Horizon Discovery Group PLC and Champions Oncology Inc.
Genetic segment by product is expected to dominate the market during the forecast period.
Explore Life Science & Biotechnology Insights
Humanized Mouse Model Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
